LIQUID-CHROMATOGRAPHIC DETERMINATION OF A NEW CATECHOL-O-METHYLTRANSFERASE INHIBITOR, ENTACAPONE, AND ITS Z-ISOMER IN HUMAN PLASMA AND URINE

被引:44
作者
KARLSSON, M
WIKBERG, T
机构
[1] Orion Corporation, Orion-Farmos Pharmaceuticals, Orion Research Center, 02101 Espoo
关键词
CATECHOL-O-METHYLTRANSFERASE INHIBITOR; ENTACAPONE AND Z-ISOMER; REVERSED-PHASE LIQUID CHROMATOGRAPHY; ELECTROCHEMICAL DETECTION; PLASMA; URINE;
D O I
10.1016/0731-7085(92)80085-2
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Assay procedures for analysis of entacapone, (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)-propenamide, and its Z-isomer in human plasma and urine are described. The methods were based on reversed-phase liquid chromatography with amperometric detection. Entacapone and its Z-isomer were extracted with n-hexane-ethyl acetate mixtures after acidification with hydrochloric acid. From urine extracts the analytes were back-extracted into phosphate buffer (pH 7.2). During sample treatment 1-2% of entacapone was changed to the Z-isomer. With recoveries exceeding 75% the relative standard deviations for within-day precision were less than 11% for plasma and less than 6% for urine at the quantitation limit (10 ng ml-1) and less than 6% for both methods at higher concentrations (20-2000 ng ml-1). The assays were specific with respect to all known metabolites and selective, sensitive and precise enough for determination of entacapone and its Z-isomer in plasma and urine down to 10 ng ml-1. The methods are thus suitable for the kind of pharmacokinetic studies exemplified in this paper.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 13 条
[1]   REDUCTION OF CIRCULATING 3-O-METHYLDOPA BY INHIBITION OF CATECHOL-O-METHYLTRANSFERASE WITH OR-611 AND OR-462 IN CYNOMOLGUS MONKEYS - IMPLICATIONS FOR THE TREATMENT OF PARKINSONS-DISEASE [J].
CEDARBAUM, JM ;
LEGER, G ;
GUTTMAN, M .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (04) :330-342
[2]   CLINICAL PHARMACOKINETICS OF ANTI-PARKINSONIAN DRUGS [J].
CEDARBAUM, JM .
CLINICAL PHARMACOKINETICS, 1987, 13 (03) :141-178
[3]   REACTIVITY CONSIDERATIONS IN THE ANALYSIS OF GLUCURONIDE AND SULFATE CONJUGATES OF DIFLUNISAL [J].
DICKINSON, RG ;
KING, AR .
THERAPEUTIC DRUG MONITORING, 1989, 11 (06) :712-720
[4]   MEASUREMENT OF PHENOL IN URINE USING A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD [J].
EADSFORTH, CV ;
COVENEY, PC .
ANALYST, 1984, 109 (02) :175-176
[5]  
GULDBERG HC, 1975, PHARMACOL REV, V27, P135
[6]   THE PHARMACOKINETICS OF INTRAVENOUS AND ORAL LEVODOPA IN PATIENTS WITH PARKINSONS-DISEASE WHO EXHIBIT ON-OFF FLUCTUATIONS [J].
HARDIE, RJ ;
MALCOLM, SL ;
LEES, AJ ;
STERN, GM ;
ALLEN, JG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (04) :429-436
[7]  
KERANEN T, 1991, Neurology, V41, P213
[8]  
Linden I.-B, 1990, MOV DISORD S1, V5, P49
[9]   NEW SELECTIVE COMT INHIBITORS - USEFUL ADJUNCTS FOR PARKINSONS-DISEASE [J].
MANNISTO, PT ;
KAAKKOLA, S .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (02) :54-56
[10]  
MANNISTO PT, 1990, PHARMACOL TOXICOL, V66, P317